Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.
Identifieur interne : 000039 ( PubMed/Corpus ); précédent : 000038; suivant : 000040Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.
Auteurs : Laure Elens ; Loralie J. Langman ; Dennis A. Hesselink ; Stein Bergan ; Dirk Jan A R. Moes ; Mariadelfina Molinaro ; Raman Venkataramanan ; Florian LemaitreSource :
- Therapeutic drug monitoring [ 1536-3694 ] ; 2020.
Abstract
COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals.
DOI: 10.1097/FTD.0000000000000761
PubMed: 32304488
Links to Exploration step
pubmed:32304488Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.</title>
<author><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name>
<affiliation><nlm:affiliation>Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, pharmacogenomics and pharmacokinetics (PMGK).</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Langman, Loralie J" sort="Langman, Loralie J" uniqKey="Langman L" first="Loralie J" last="Langman">Loralie J. Langman</name>
<affiliation><nlm:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hesselink, Dennis A" sort="Hesselink, Dennis A" uniqKey="Hesselink D" first="Dennis A" last="Hesselink">Dennis A. Hesselink</name>
<affiliation><nlm:affiliation>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bergan, Stein" sort="Bergan, Stein" uniqKey="Bergan S" first="Stein" last="Bergan">Stein Bergan</name>
<affiliation><nlm:affiliation>Oslo University Hospital, Department of Pharmacology, Oslo, Norway.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moes, Dirk Jan A R" sort="Moes, Dirk Jan A R" uniqKey="Moes D" first="Dirk Jan A R" last="Moes">Dirk Jan A R. Moes</name>
<affiliation><nlm:affiliation>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Molinaro, Mariadelfina" sort="Molinaro, Mariadelfina" uniqKey="Molinaro M" first="Mariadelfina" last="Molinaro">Mariadelfina Molinaro</name>
<affiliation><nlm:affiliation>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Venkataramanan, Raman" sort="Venkataramanan, Raman" uniqKey="Venkataramanan R" first="Raman" last="Venkataramanan">Raman Venkataramanan</name>
<affiliation><nlm:affiliation>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name>
<affiliation><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes, France.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32304488</idno>
<idno type="pmid">32304488</idno>
<idno type="doi">10.1097/FTD.0000000000000761</idno>
<idno type="wicri:Area/PubMed/Corpus">000039</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000039</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.</title>
<author><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name>
<affiliation><nlm:affiliation>Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, pharmacogenomics and pharmacokinetics (PMGK).</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Langman, Loralie J" sort="Langman, Loralie J" uniqKey="Langman L" first="Loralie J" last="Langman">Loralie J. Langman</name>
<affiliation><nlm:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hesselink, Dennis A" sort="Hesselink, Dennis A" uniqKey="Hesselink D" first="Dennis A" last="Hesselink">Dennis A. Hesselink</name>
<affiliation><nlm:affiliation>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bergan, Stein" sort="Bergan, Stein" uniqKey="Bergan S" first="Stein" last="Bergan">Stein Bergan</name>
<affiliation><nlm:affiliation>Oslo University Hospital, Department of Pharmacology, Oslo, Norway.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moes, Dirk Jan A R" sort="Moes, Dirk Jan A R" uniqKey="Moes D" first="Dirk Jan A R" last="Moes">Dirk Jan A R. Moes</name>
<affiliation><nlm:affiliation>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Molinaro, Mariadelfina" sort="Molinaro, Mariadelfina" uniqKey="Molinaro M" first="Mariadelfina" last="Molinaro">Mariadelfina Molinaro</name>
<affiliation><nlm:affiliation>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Venkataramanan, Raman" sort="Venkataramanan, Raman" uniqKey="Venkataramanan R" first="Raman" last="Venkataramanan">Raman Venkataramanan</name>
<affiliation><nlm:affiliation>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name>
<affiliation><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes, France.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Therapeutic drug monitoring</title>
<idno type="eISSN">1536-3694</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32304488</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-3694</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Therapeutic drug monitoring</Title>
<ISOAbbreviation>Ther Drug Monit</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/FTD.0000000000000761</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of immunosuppressive drugs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining immunosuppressive drug concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">With the present manuscript, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elens</LastName>
<ForeName>Laure</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, pharmacogenomics and pharmacokinetics (PMGK).</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Université catholique de Louvain (UCLouvain), Institut de Recherche Expérimentale et Clinique (IREC), Louvain center for toxicology and applied pharmacology (LTAP).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Langman</LastName>
<ForeName>Loralie J</ForeName>
<Initials>LJ</Initials>
<AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hesselink</LastName>
<ForeName>Dennis A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo><Affiliation>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Rotterdam Transplant Group.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bergan</LastName>
<ForeName>Stein</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Oslo University Hospital, Department of Pharmacology, Oslo, Norway.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moes</LastName>
<ForeName>Dirk Jan A R</ForeName>
<Initials>DJAR</Initials>
<AffiliationInfo><Affiliation>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molinaro</LastName>
<ForeName>Mariadelfina</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Venkataramanan</LastName>
<ForeName>Raman</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lemaitre</LastName>
<ForeName>Florian</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Ther Drug Monit</MedlineTA>
<NlmUniqueID>7909660</NlmUniqueID>
<ISSNLinking>0163-4356</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32304488</ArticleId>
<ArticleId IdType="doi">10.1097/FTD.0000000000000761</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000039 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000039 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:32304488 |texte= Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32304488" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |